What is Desentum?
Founded in 2011 as a spin-off from the VTT Technical Research Centre of Finland, Desentum is headquartered in Espoo, Finland. The company's core innovation lies in its proprietary allergen immunotherapy platform, which utilizes modified hypoallergens to re-educate the immune system. This approach aims to convert allergic hypersensitivity into a state of tolerance. The scientific foundation of Desentum's technology was recognized in 2013 when VTT received an EARTO Innovation Prize for the underlying work. The company has demonstrated its commitment to clinical validation, having been awarded a 1.9 M€ grant from the Horizon 2020 SME instrument in 2018 to support its first-in-human clinical trials and broader business development initiatives.
How much funding has Desentum raised?
Desentum has raised a total of $15.5M across 3 funding rounds:
Series A
$2M
Other Financing Round
$4.5M
Unspecified
$9M
Series A (2017): $2M, investors not publicly disclosed
Other Financing Round (2019): $4.5M, investors not publicly disclosed
Unspecified (2022): $9M supported by Springvest Oyj
Key Investors in Desentum
Springvest Oyj
Springvest Oyj is an investment company that appears to be a significant backer in Desentum's funding rounds, indicating a strategic interest in the biopharmaceutical sector.
What's next for Desentum?
With the recent influx of major strategic capital, Desentum is poised to accelerate its development pipeline and expand its market reach. The enterprise-level backing suggests confidence from investors in the company's innovative immunotherapy approach and its potential to address unmet needs in allergy treatment. Future endeavors will likely focus on advancing clinical trials, scaling manufacturing capabilities, and potentially forging strategic partnerships to bring its novel hypoallergen-based therapies to patients globally. The company's trajectory indicates a move towards commercialization and broader market penetration.
See full Desentum company page
